Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK-011 in Advanced Solid Tumors
NCT04906434Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Feb 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of irpagratinib in solid tumor and hepatocellular carcinoma (HCC), sponsored by Abbisko Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Adverse Events at 6 months and 6 more. Started Feb 2020; status: recruiting.
02
Drugs
irpagratinib
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04906434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906434.